Clinical Trial Update: Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cemiplimab given before surgery in patients with recurrent and resectable stage II-IV head and neck cutaneous squamous cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Cemiplimab (cemiplimab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: ACTIVE_NOT_RECRUITING